Our vision is to be the preferred technology partner by providing a one-stop solution that enables any company with a pre-existing antibody to rapidly generate a proprietary clinical-stage ADC that is significantly more effective, better tolerated as well as easier to manufacture.
We can generate nonclinical proof-of-concept (POC) material in just a few weeks. Further, we enable rapid development of proprietary ADC products by our partners with a timeline to IND filing as short as 12 months from preclinical POC. This is made possible by our proprietary ADC technologies that include toxSYN™ ADC payloads, GlycoConnect™ and HydraSpace™, which can be accessed by partners on a target-specific basis. As a first step, we welcome the opportunity to showcase the advantages of our proprietary approach under a joint POC study.
The potential of our technology also extends beyond ADCs, to areas such as targeted delivery, conjugated vaccines, imaging and diagnostics, which we continue to explore with interested partners.
In October 2016, Synaffix entered into a non-exclusive, target-specific license agreement with ADC Therapeutics. In October, 2017, ADC Therapeutics triggered a second license under that same Agreement.
In January 2019, Synaffix entered into an additional non-exclusive, target-specific license agreement with Mersana Therapeutics.
For more information on partnering with Synaffix, please contact:
Director, Business Development
+31 620 773 194
Pivot Park, RE-1320
5349 AE Oss, Netherlands